BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 26049707)

  • 1. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test.
    Korkmaz H; Unler GK; Gokturk HS; Schmidt WE; Kebapcilar L
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1137-43. PubMed ID: 26049707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 13C-Methacetin Breath Testing in Patients with Non-Alcoholic Fatty Liver Disease.
    Kempiński R; Neubauer K; Wieczorek S; Dudkowiak R; Jasińska M; Poniewierka E
    Adv Clin Exp Med; 2016; 25(1):77-81. PubMed ID: 26935501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The non-invasive (13)C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis.
    Banasch M; Ellrichmann M; Tannapfel A; Schmidt WE; Goetze O
    Eur J Med Res; 2011 Jun; 16(6):258-64. PubMed ID: 21810560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters.
    Chunming L; Jianhui S; Hongguang Z; Chunwu Q; Xiaoyun H; Lijun Y; Xuejun Y
    Turk J Gastroenterol; 2015 Sep; 26(5):408-16. PubMed ID: 26215061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis.
    Golabi P; Sayiner M; Fazel Y; Koenig A; Henry L; Younossi ZM
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):63-71. PubMed ID: 26469309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of ¹³C-methacetin breath test for the non-invasive evaluation of nonalcoholic fatty liver disease.
    Fierbinteanu-Braticevici C; Plesca DA; Tribus L; Panaitescu E; Braticevici B
    J Gastrointestin Liver Dis; 2013 Jun; 22(2):149-56. PubMed ID: 23799213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Fierbinteanu-Braticevici C; Baicus C; Tribus L; Papacocea R
    J Gastrointestin Liver Dis; 2011 Jun; 20(2):153-9. PubMed ID: 21725512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
    PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
    Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
    Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
    Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis.
    Cengiz M; Ozenirler S; Kocabiyik M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):57-63. PubMed ID: 26513612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease.
    Maleki I; Aminafshari MR; Taghvaei T; Hosseini V; Rafiei A; Torabizadeh Z; Barzin M; Orang E
    World J Gastroenterol; 2014 Sep; 20(35):12566-73. PubMed ID: 25253959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 18. Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adults: Association of GGT and HOMA-IR with NAFLD.
    Hossain IA; Rahman Shah MM; Rahman MK; Ali L
    Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S25-9. PubMed ID: 26482965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
    Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
    Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining.
    Yoshimura K; Okanoue T; Ebise H; Iwasaki T; Mizuno M; Shima T; Ichihara J; Yamazaki K
    Hepatology; 2016 Feb; 63(2):462-73. PubMed ID: 26390046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.